SCHEMBL184686

SCHEMBL184686

N#Cc1ccc(Oc2cnc(N)s2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.44
CYP3A4 P08684 1/20 0.42
SCN9A Q15858 2/20 0.42
KCNH2 Q12809 1/20 0.42
SCN5A Q14524 1/20 0.42
MAP4K4 O95819 1/20 0.42
PARP15 Q460N3 1/20 0.41
PARP10 Q53GL7 1/20 0.41
PARP2 Q9UGN5 1/20 0.41
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA9 Q16790 2/20 0.40
ICAM1 P05362 1/20 0.40
SELE P16581 1/20 0.40
VCAM1 P19320 1/20 0.40
CCNC P24863 1/20 0.40
CDK8 P49336 1/20 0.40
CA12 O43570 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2667220 0.82 MAP4K4 (0.46) CYP19A1MAP4K4
SCHEMBL2655449 0.78 TEAD4 (0.47) CYP3A4SCN9AKCNH2SCN5AMAP4K4
SCHEMBL12475874 0.78 NOS1 (0.35) MYCWDR5MAPTRAB9APOLB
SCHEMBL30642785 0.78 EPHX2 (0.47) MAP4K4CA1CA2CA9ICAM1
SCHEMBL3772542 0.78 GAA (0.50) SCN9AKCNH2SCN5ACA1CA2
SCHEMBL184691 0.74 ALDH1A1 (0.47) PARP10MAPTRAB9APOLBKDM4E
SCHEMBL10329778 0.72 MAP4K4 (0.43) MAP4K4CCNCCDK8MAPTRAB9A
SCHEMBL12475998 0.72 TSHR (0.54) ICAM1SELEMAPTRAB9APOLB
SCHEMBL12476000 0.72 POLB (0.42) MAPTRAB9APOLBKDM4EMEN1
SCHEMBL22685011 0.71 CSNK2A1 (0.54) MAP4K4CYP11B2MYCWDR5MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114845709-B MRGPRX2 antagonists for the treatment of inflammatory disorders 德米拉公司 2024-10-01 CN disclosed
EP-4054554-A1 MRGPRX2 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS Dermira, Inc (US) 2022-09-14 EP disclosed
CN-114845709-A MRGPRX2 antagonists for use in treating inflammatory disorders 德米拉公司 2022-08-02 CN disclosed
EP-2402327-B1 Acetamide compounds as glucokinase activators, their process and medicinal applications IMPETIS BIOSCIENCES LTD (IN) 2018-03-07 EP disclosed
US-8501955-B2 Acetamide derivatives as glucokinase activators, their process and medicinal application ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2013-08-06 US disclosed
EP-2402327-A1 Acetamide compounds as glucokinase activators, their process and medicinal applications Advinus Therapeutics Private Limited (IN) 2012-01-04 EP disclosed
US-20100310493-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2010-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100310493-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION GCK, GCKR, ALDOA CYP19A1 1111/4885CYP3A4 415/4885SCN9A 2279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.